Shots:

• The first P-II NCT03860038 trial involves assessing of TJ202/MOR202 as a 3L treatment in patients with R/R MM while the second P-II trial assess TJ202/MOR202 + lenalidomide (LEN) + dexamethasone (DEX) vs LEN + DEX in 1L R/R MM
• In 2017- I-Mab in-licensed TJ202/MOR202 from MorphoSys while holds exclusive rights to develop and commercialize it in Mainland China- Hong Kong- Macao and Taiwan and is targeting the candidate in multiple myeloma and in certain autoimmune diseases- including systemic lupus erythematosus
• TJ202/MOR202 is a mAb developed using MorphoSys’ HuCAL antibody technology used for targeting CD38 cells present on the surface of multiple myeloma cells

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance